| Cardiovascular Risk Management |
1 |
1 |
| Weight Management |
0 |
1 |
| Weight Loss |
0 |
0.96 |
| Obesity |
0 |
0.76 |
| Heart |
0 |
0.18 |
| Cerebrovascular Accident |
0 |
0.17 |
| Type 2 Diabetes Mellitus |
0 |
0.12 |
| GLP-1 Receptor Agonist |
0 |
0.1 |
| Blood Vessel |
0 |
0.09 |
| Health Insurance |
0 |
0.09 |
| Revenue and Practice Management |
0 |
0.09 |
| Adverse Effects |
0 |
0.06 |
| Blood |
0 |
0.06 |
| Cardiovascular disease |
0 |
0.06 |
| Incretin Hormone |
0 |
0.06 |
| Infarction |
0 |
0.06 |
| Insurance |
0 |
0.06 |
| Medicare |
0 |
0.06 |
| Metabolism |
0 |
0.06 |
| Myocardial Infarction (MI) |
0 |
0.06 |
| Patient Safety |
0 |
0.06 |
| Plantar |
0 |
0.06 |
| Quality of Life |
0 |
0.06 |
| Receptors |
0 |
0.06 |
| Tolerance |
0 |
0.06 |